---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-029007"
form_type: "8-K"
ticker: "BGMS"
cik: "0001130166"
company_name: "Bio Green Med Solution, Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:09:17.478993+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cyclacel Q4 net loss $7.4M, cash $18.3M; fadraciclib Phase 2 on track for 1H 2023

## Summary
- Net loss Q4 2022 $7.4M, full year $21.2M; cash $18.3M as of Dec 31, 2022.
- R&D expenses $6.7M (Q4) and $20.3M (FY) driven by fadraciclib and plogosertib trials.
- Cash runway estimated into Q4 2023 including $4.7M UK R&D tax credit receivable.
- On track to start oral fadraciclib Phase 2 proof-of-concept in 1H 2023; interim data expected 2H 2023.
- Expect final data from fadraciclib dose escalation and initial data from plogosertib dose escalation in 2023.

## SEC filing metadata
- accession: 0001104659-23-029007
- form_type: 8-K
- ticker: BGMS
- cik: 0001130166
- company_name: Bio Green Med Solution, Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130166/000110465923029007/0001104659-23-029007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130166/000110465923029007/tm238618d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-029007
- JSON: https://secwatch.observer/filing/0001104659-23-029007.json
- Plain text: https://secwatch.observer/filing/0001104659-23-029007.txt

## Key facts
- Earnings Releases
  Bio Green Med Solution, Inc. reported the year ended December 31, 2022 results: net income $21.2 million.
  - Period: the year ended December 31, 2022
  - Net income: $21.2 million
  - Result: reported results
  source text: Net loss for the three months and year ended December 31, 2022, was $7.4 million and $21.2 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130166/000110465923029007/0001104659-23-029007-index.htm
- Earnings Releases
  Bio Green Med Solution, Inc. reported the three months ended December 31, 2022 results: net income $7.4 million.
  - Period: the three months ended December 31, 2022
  - Net income: $7.4 million
  - Result: reported results
  source text: Net loss for the three months and year ended December 31, 2022, was $7.4 million and $21.2 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130166/000110465923029007/0001104659-23-029007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.